Tien-Li Lee - 12 Feb 2025 Form 3 Insider Report for Aardvark Therapeutics, Inc. (AARD)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Tien-Li Lee
Issuer symbol
AARD
Transactions as of
12 Feb 2025
Net transactions value
$0
Form type
3
Filing time
12 Feb 2025, 18:49:52 UTC
Previous filing
17 Jan 2023
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AARD Common Stock 1,438,330 12 Feb 2025 Direct
holding AARD Common Stock 1,474,028 12 Feb 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AARD Series A Convertible Preferred Stock 12 Feb 2025 Common Stock 41,303 Direct F1
holding AARD Stock Option (Right to Buy) 12 Feb 2025 Common Stock 59,004 $4.24 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") is convertible into shares of common stock of the Issuer ("Common Stock") at the holder's election on an 8.474-for-1 basis and has no expiration date. All shares of Series A Convertible Preferred Stock will automatically convert on an 8.474-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 1/48th of the original number of shares subject to the option vested on July 27, 2024, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney